Hanmi Pharm. Co., Ltd. Logo

Hanmi Pharm. Co., Ltd.

Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.

128940 | KO

Overview

Corporate Details

ISIN(s):
KR7128940004
LEI:
Country:
South Korea
Address:
경기도 화성시 팔탄면 무하로 214, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hanmi Pharmaceutical Co., Ltd., established in 1973, is a leading South Korean biopharmaceutical company with a strong focus on research and development. The company develops, manufactures, and markets a broad portfolio of in-house medicines, including prescription drugs, over-the-counter (OTC) products, medical supplies, and raw materials. Hanmi is recognized for its innovative drug development, particularly in the therapeutic areas of diabetes and cancer, and is committed to providing advanced medical solutions to healthcare professionals and patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.1 KB
2025-09-03 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항
Korean 13.3 KB
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 46.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.4 MB
2025-08-14 00:00
Interim Report
[기재정정]반기보고서 (2025.06)
Korean 3.5 MB
2025-08-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 59.1 KB
2025-08-01 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 31.0 KB
2025-07-28 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.0 KB
2025-07-25 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.5 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 92.2 KB
2025-07-18 00:00
Report Publication Announcement
결산실적공시예고(안내공시)
Korean 4.4 KB
2025-07-18 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.1 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 53.2 KB
2025-07-01 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.1 KB
2025-06-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 72.8 KB

Automate Your Workflow. Get a real-time feed of all Hanmi Pharm. Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hanmi Pharm. Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hanmi Pharm. Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.